Parkinson’s research reaches “pivotal” stage, but barriers remain
Preclinical and clinical research focused on Parkinson’s disease has reached a “pivotal point”, but funding barriers and outdated clinical trial …
Post
-
-
WHO directs antibiotic development to priority pathogens
The World Health Organization (WHO) has outlined desired antibacterial characteristics for three priority infections as part of a move to …
-
PRISM BioLab partners with Receptor.AI for molecule discovery
PRISM BioLab has formed a collaboration with Receptor.AI to integrate AI and physics-guided technologies in the discovery of orally available …
-
PsiQuantum and National Cancer Center Japan partner on quantum computing
PsiQuantum and the National Cancer Center Japan have entered a collaborative research agreement to drive advancements in utility-scale quantum computing …
-
Vima banks $100m in Series A to progress Parkinson’s drug
Massachusetts-based biotech Vima Therapeutics has extended its Series A financing by $40m to advance its investigational Parkinson’s and dystonia pill, …
-
Eli Lilly finds impurity in compounded tirzepatide
Eli Lilly has warned of high levels of an impurity in certain compounded versions of its blockbuster glucagon-like peptide-1 receptor …
-
Wegovy portfolio growth shifts to the pill as injectable sales forecast to plateau
In December 2025, the FDA approved the first-ever GLP-1 pill for chronic weight management - Novo Nordisk’s oral formulation of …
-
Bavarian Nordic and SII sign agreement for chikungunya vaccine production
Bavarian Nordic has signed a manufacturing agreement with Serum Institute of India (SII), expanding its strategic partnership through a contract …
-
Curatis and Neupharma sign development agreement for corticorelin in Japan
Switzerland-based Curatis has signed an exclusive licensing and development agreement with Neupharma for corticorelin (C-PTBE-01) to treat peritumoral brain oedema …
-
FDA issues warning to Novo Nordisk on unreported semaglutide safety events
Novo Nordisk has received a warning letter from the US Food and Drug Administration (FDA) related to the company’s failure …
-
Tariffs, uncertainty and disruption: how drug makers and distributors can build operational supply chain resilience
Ryan Rotar, vice president of healthcare market strategy at Tecsys, outlines how supply chain resilience can be maintained in the …
-
Eli Lilly to invest $3bn in China in anticipation of orforglipron approval
Eli Lilly is continuing its global investment drive to ensure it can meet future demand for its highly anticipated oral …
-
BioNTech co-founders step down to launch new mRNA venture
The co-founders of BioNTech will leave the company to launch a new mRNA-focused entity, amid mounting losses for the vaccine …
-
UK health authorities join forces to champion foreign infectious disease trials
Health divisions within the UK government and British non-profit organisations have banded together to support infectious disease trials in Africa, …
-
Idorsia and Pharmalink sign agreement to distribute Quviviq
Idorsia has signed an exclusive agreement with Pharmalink Drug Store to distribute and commercialise its Quviviq (daridorexant) insomnia therapy in …
